Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvastatic in breast cancer patients undergoing chemotherapy
NCT07669506Phase 3Completed
- Sponsor
- Natureceuticals
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer-related fatigue (CRF) comparing Placebo with Nuvastatic ™ (2 arms). Primary endpoint: Brief Fatigue Inventory at 12 weeks. Started Jun 2025; status: completed.
02
Drugs
Nuvastatic
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT07669506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07669506.